title: Clinical Trials of Antiangiogenesis Therapy in Recurrent/Persistent and Metastatic Cervical Cancer.
abstract: Treatment options for women with metastatic, persistent, or recurrent cervical cancer are limited and thus the disease portends a poor prognosis. It is critical to understand the pathophysiology of cervical cancer to better delineate therapeutic targets. The development of antiangiogenic therapies and their subsequent analysis in rigorous therapeutic trials have redefined current management strategies and is an exciting area of current exploration.
  
  
  
  Translational trials have furthered the understanding of molecular determinants of angiogenesis. Phase II trials have shown promising trends with developing antiangiogenic therapies. A practice-changing phase III trial has recently been published. Given the potential benefits and different toxicity spectrum compared with standard cytotoxic chemotherapy, antiangiogenic options are under active investigation for this vulnerable patient population. Emerging data are promising for other antiangiogenic-directed therapeutics, as well as cervical cancer molecular biomarkers to guide diagnosis and treatment.
  
  
  
  Antiangiogenic therapies have evolved during the past 20 years and remain an exciting area of current exploration.
  
  
  
  Understanding of the angiogenic microenvironment has furthered understanding of tumor biology and management. Antiangiogenic therapies show promise for women with advanced cervical cancer. A review of the evolution of these biologic agents shows them to be an effective and tolerable management strategy for many patients in this vulnerable population, with exciting future potential.
authors.affiliation: University of California, Irvine, Orange, California, USA.
authors.forename: Jill K
authors.initials: JK
authors.lastname: Alldredge
authors.affiliation: University of California, Irvine, Orange, California, USA ktewari@uci.edu.
authors.forename: Krishnansu S
authors.initials: KS
authors.lastname: Tewari
mesh_terms: D020533:Angiogenesis Inhibitors / Q000627:therapeutic use*; D000068258:Bevacizumab / Q000627:therapeutic use; D002986:Clinical Trials as Topic; D003510:Cyclohexanes / Q000627:therapeutic use; D005260:Female; D006801:Humans; D009362:Neoplasm Metastasis; D009364:Neoplasm Recurrence, Local / Q000188:drug therapy*; D000077609:O-(Chloroacetylcarbamoyl)fumagillol; D011379:Prognosis; D012717:Sesquiterpenes / Q000627:therapeutic use; D002583:Uterine Cervical Neoplasms / Q000098:blood supply / Q000188:drug therapy* / Q000401:mortality / Q000473:pathology
chemical_list: D020533:Angiogenesis Inhibitors; D003510:Cyclohexanes; D012717:Sesquiterpenes; D000068258:Bevacizumab; D000077609:O-(Chloroacetylcarbamoyl)fumagillol
keywords: Angiogenesis inhibitors; Antiangiogenesis therapy; Biological markers; Biomarkers; Cervical cancer; Clinical trials; Uterine cervical neoplasms